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Abstract
Background:  Many researchers are interested to know if there are any improvements in recent
treatment results for metastatic breast cancer in the community, especially for 10- or 15-year survival.
Methods: Between 1981 and 1985, 782 and 580 female patients with metastatic breast cancer were
extracted respectively from the Connecticut and San Francisco-Oakland registries of the Surveillance,
Epidemiology, and End Results (SEER) database. The lognormal statistical method to estimate survival was
retrospectively validated since the 15-year cause-specific survival rates could be calculated using the
standard life-table actuarial method. Estimated rates were compared to the actuarial data available in 2000.
Between 1991 and 1995, further 752 and 632 female patients with metastatic breast cancer were extracted
respectively from the Connecticut and San Francisco-Oakland registries. The data were analyzed to
estimate the 15-year cause-specific survival rates before the year 2005.
Results: The 5-year period (1981–1985) was chosen, and patients were followed as a cohort for an
additional 3 years. The estimated 15-year cause-specific survival rates were 7.1% (95% confidence interval,
CI, 1.8–12.4) and 9.1% (95% CI, 3.8–14.4) by the lognormal model for the two registries of Connecticut
and San Francisco-Oakland respectively. Since the SEER database provides follow-up information to the
end of the year 2000, actuarial calculation can be performed to confirm (validate) the estimation. The
Kaplan-Meier calculation for the 15-year cause-specific survival rates were 8.3% (95% CI, 5.8–10.8) and
7.0% (95% CI, 4.3–9.7) respectively. Using the 1991–1995 5-year period cohort and followed for an
additional 3 years, the 15-year cause-specific survival rates were estimated to be 9.1% (95% CI, 3.8–14.4)
and 14.7% (95% CI, 9.8–19.6) for the two registries of Connecticut and San Francisco-Oakland
respectively.
Conclusions: For the period 1981–1985, the 15-year cause-specific survival for the Connecticut and the
San Francisco-Oakland registries were comparable. For the period 1991–1995, there was not much
change in survival for the Connecticut registry patients, but there was an improvement in survival for the
San Francisco-Oakland registry patients.
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Background
Prospective trials have the disadvantages of requiring a
long time to complete, and using highly selected patient
subgroups in tertiary centers. While one waits for the
results to mature, this delays additional research to
improve treatment. If there were a method that allowed
earlier prediction of the results of prospective trials,
advances in cancer treatment could be attained within a
shorter time period.
There is a parametric lognormal model, proposed by Boag
[1-3] that had been retrospectively validated in the litera-
ture, and could be used prospectively for clinical trials to
predict long-term survival rates several years earlier than
would otherwise be possible using the standard life-table/
actuarial Kaplan-Meier method of calculation [4].
The prognosis for metastatic breast cancer is generally
poor and therefore it is believed that statistical prediction
models for long-term survival rates are not needed. Never-
theless, specific subgroups of metastatic breast cancer
patients exist, for which depending on the treatment
given, the prognosis is improved so that some patients can
survive for some time, particularly for those with limited
organs involvement such as involvement with bone and/
or skin only. In this situation, for which the present study
was relevant, a prediction model, even for metastatic
breast cancer, can be useful.
Breast cancer, among other cancers, has the highest inci-
dence in women, and many studies are currently in
progress to assess treatment regimens. If, even for a sub-
group of patients, the 10- and 15-year survival rates can be
predicted from follow-up data available only 3 years after
a 5-year diagnosis period, this would be a useful means of
obtaining study results earlier than would otherwise have
been possible. For example, a 15-year survival rate calcu-
lated by the Kaplan-Meier method requires at least some
patients to have been followed for 15 years. In addition
prediction model such as the lognormal model can also
be used to review the progress of treatment results for a
specific period from a treatment center, and to compare
that with another specific period of the same treatment
center to evaluate the potential impact for any possible
change in treatment policy or guideline.
Boag's lognormal model for long-term cancer survival
rates has been available for use for some 50 years. When
the lognormal model was first proposed in the 1940s, it
was difficult to implement because of a lack of computing
power, and lack of good quality long-term follow-up data
from cancer registries. Since 1970s the model has been
used by some authors in breast cancer, cervix uteri cancer,
head and neck cancer, intraocular melanoma, choroidal-
ciliary body melanoma, and small cell lung cancer [5-10].
Currently, although the computing power is sufficient,
good quality follow-up data on a sufficient number of
patients are seldom available, and it can be a limitation
for its application. Large data registry such as the Surveil-
lance, Epidemiology, and End Results (SEER) data [11]
with good long-term follow-up data available can over-
come this potential limitation.
Methods
Between 1981 and 1985, 782 and 580 female patients of
metastatic breast cancer were extracted respectively from
the Connecticut and San Francisco-Oakland registries
from the SEER database using SEER*Stat 5.0 software. The
two registries were chosen because they are two of the ear-
liest registries, with a large population. The data used were
survival time, vital status, cause of death, age at diagnosis,
and race.
The cause-specific survival was defined as the interval
from the date of diagnosis to the date of death from breast
cancer or the last follow-up date for censoring purposes, if
the patient was alive and still being followed at the time
of analysis. The survival time of the uncured group of
patients who died of breast cancer had been verified to
follow a lognormal distribution previously [12].
Next, between 1991 and 1995, 752 and 632 female
patients of metastatic breast cancer were extracted respec-
tively from the two registries. The data were used to esti-
mate the 15-year cause-specific survival rates before the
year 2005. To be comparable, for both the 1981–1985
and 1991–1995 cohorts, the staging system used was the
SEER historical system (classified as localized, regional, or
distant, based on combined pathologic and clinical data).
The choice of 1981–1985 and 1991–1995 has the advan-
tage that the two time periods are not too far apart other-
wise there would be too much changes of medical
practice. These time periods have a minimum of 5 years
follow-up.
The overall survival rates (OSR) of the two time periods
were calculated using the Kaplan-Meier method. The
actual relative survival rates (RSR) were calculated using
SEER*Stat 5.0 software. The modified version of period
analysis [13] was applied using the Hakulinen method
[14] to obtain more up-to-date absolute survival rates
(ASR) and relative survival rates (RSR) for comparison
purpose with a computer program run by Microsoft Excel
software.
Validation of the lognormal model
The validation of the lognormal model has two phases.
Phase 1 tests the goodness of fit to a lognormal distribu-
tion of the survival time of those cancer patients who died
with their disease present, termed an uncured group withBMC Cancer 2004, 4:60 http://www.biomedcentral.com/1471-2407/4/60
Page 3 of 8
(page number not for citation purposes)
a fraction of 1-C, where C is the cured proportion of
patients. The lognormal distribution is similar to the nor-
mal distribution in that if the variable in the normal is
time t, the variable in the lognormal is the logarithm of t.
In other words, the investigators attempt to show that the
logarithm of the survival time follows a normal distribu-
tion. Phase 2 attempts to show that the lognormal model,
using short-term follow-up data, can predict long-term
survival rates comparable to those calculated by the Kap-
lan-Meier life-table method with long-term available. This
model can be used to estimate long-term cause-specific
survival rates (CSSR) by a maximum likelihood method
(e.g., 10-year and 15-year survival rates) from only short-
term follow-up data. The maximum likelihood method is
used to estimate the CSSR at time τ, and is calculated as
[C+(1-C)·Q]·100%, where Q is the integral of the log-
normal distribution between the limits time τ and
infinity.
The lognormal statistical model had been validated in
stages III and IV breast cancer in a previous publication
that survival rates could be estimated several years earlier
than is possible using the standard life-table actuarial
method [12]. The survival time of unsuccessfully treated
cases could be represented by a lognormal distribution,
the long-term survival rates were predicted by Boag's
method using a computer program run by Microsoft
Excel. In this parametric lognormal model, the standard
deviation S was fixed, and only the two remaining param-
eters, mean M and proportion cured C, were kept floating
when using the maximum likelihood method. Multiple
iterations converged to a stable solution for C.
A 5-year period of diagnosis could be selected and
patients followed as a cohort for an additional 3 years.
The current study was for metastatic breast cancer patients
treated between 1981 and 1985, with follow-up to the
end of year 2000, making the series ideal for validating
purposes. For example, for cases diagnosed during the 5-
year period, prediction of the 15-year survival rate was
made using data at the follow-up cutoff date of December
31, 1988 (i.e., 3 years after 1985). The 15-year survival
rate prediction was then validated by Kaplan-Meier life-
table calculations using the follow-up data available in
2000.
For metastatic breast cancer patients treated between 1991
and 1995, and follow-up to the end of year 2000, predic-
tion of the 15-year survival rate was made using data at the
follow-up cutoff date of December 31, 1998 (i.e., 3 years
after 1995) before the year 2005.
Results
From the cohort of 1981–1985 inclusively, 782 patients
from the Connecticut registry were followed to the end of
1988. The lognormal model predicted the 15-year CSSR
to be 7.1% (95% CI, 1.8–12.4). The 15-year CSSR was
8.3% (95% CI, 5.8–10.8) validated by the Kaplan-Meier
calculation using actuarial follow-up data up to the end of
year 2000.
From the cohort of 1981–1985 inclusively, 580 patients
from the San Francisco-Oakland registry were followed to
the end of 1988. The lognormal model predicted the 15-
year CSSR to be 9.2% (95% CI, 3.9–14.5). The 15-year
CSSR was 7.0% (95% CI, 4.3–9.7) validated by the Kap-
lan-Meier calculation using actuarial follow-up data up to
the end of year 2000.
Using the same method, the cohort of 1991–1995 inclu-
sively, 752 patients from the Connecticut registry were fol-
lowed to the end of 1998. The lognormal model predicted
the 10-year CSSR to be 12.6% (95% CI, 7.3–17.9). The
10-year CSSR was 11.3% (95% CI, 7.8–14.8) validated by
the Kaplan-Meier calculation using actuarial follow-up
data up to the end of year 2000. The lognormal model
predicted the 15-year CSSR to be 9.1% (95% CI, 3.8–
14.4), which cannot be validated before 2005.
For the cohort of 1991–1995 inclusively, 632 patients
from the San Francisco-Oakland registry were followed to
the end of 1998. The lognormal model predicted the 10-
year CSSR to be 17.0% (95% CI, 12.1–21.9). The 10-year
CSSR was 15.9% (95% CI, 11.4–20.4) validated by the
Kaplan-Meier calculation using actuarial follow-up data
up to the end of year 2000. The lognormal model pre-
dicted the 15-year CSSR to be 14.7% (95% CI, 9.8–19.6),
which cannot be validated before 2005.
For the period 1991–1995, there was not much change of
only about 2% absolute percentage point in the predicted
15-year CSSR for the Connecticut registry, but there was
an improvement of about 6% absolute percentage points
for the San Francisco-Oakland registry when compared
with the period 1981–1985 15-year CSSR, which was val-
idated by the Kaplan-Meier calculation. (Table 1)
For comparison purpose, the actual OSR and RSR were
compared with the ASR and RSR obtained by the period
analysis. (Tables 2 and 3) It was found that there were
more patient survival improvements shown in the actual
OSR and RSR for the San Francisco-Oakland registry, but
not much for the Connecticut registry. However the
period analysis results did not show such improvements.
Discussion
Lognormal model
Rutqvist studied the fit of Boag's lognormal model to the
survival times of 8170 breast cancer cases reported to the
Swedish Cancer Registry during 1961–1963. The modelBMC Cancer 2004, 4:60 http://www.biomedcentral.com/1471-2407/4/60
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fitted the 1961–1963 data well for the entire case material
and for patients aged less than 70 years. In this registry,
the lognormal model did not fit the data for patients aged
greater than 70 years, who were more likely to be censored
because of coincidental causes of death. Another disad-
vantage stated by the author was that large number of
patients was required to obtain estimates with reasonably
small standard errors for breast cancer.
With another series of the Norwegian Cancer Registry of
14,000 breast cancer cases, Rutqvist et al. [15] deduced
that lognormal is the best model because other models
did not fit the observed survival in all stages, ages, and
time periods (two-parameter models, such as exponential
or extrapolated actuarial, or three-parameter models, such
as sum of two exponential, exponential with shoulder,
Weibull). Both the exponential and extrapolated actuarial
models assume that the conditional relative survival is
lowest immediately after treatment. With the lognormal
model, the survival curve has a low initial mortality that
rapidly increases to a maximum, with a slow decrease in
the mortality after the maximum has occurred.
Table 1: 10- and 15-year cause-specific survival rates for Connecticut and San Francisco-Oakland registries for 1981–1985 and 1991–
1995 cohorts calculated by lognormal model (LN) and Kaplan-Meier (KM) method with 95% confidence intervals in brackets
Connecticut San Francisco-Oakland
Year 1981–1985 1991–1995 1981–1985 1991–1995
LN KM LN KM LN KM LN KM
10 11.5 (6.2–16.8) 11.0 (8.5–13.5) 12.6 (7.3–17.9) 11.3 (7.8–14.8) 12.3 (7.0–17.6) 9.7(6.8–12.6) 17.0 (12.1–21.9) 15.9 (11.4–20.4)
15 7.1 (1.8–12.4) 8.3 (5.8–10.8) 9.1 (3.8–14.4) N.A. 9.2 (3.9–14.5) 7.0 (4.3–9.7) 14.7 (9.8–19.6) N.A.
N.A. = not available




OSRa RSRb ASRc RSRd OSRa RSRb ASRc RSRd
10 6.4 (4.6–8.2) 9.1 (6.7–11.5) 13.0 (12.2–13.8) 16.7 (15.7–17.7) 7.2 (3.7–10.7) 9.7 (6.4–13.0) 15.6 (14.6–16.6) 20.7 (19.5–21.9)
15 3.2 (2.0–4.4) 5.7 (3.5–7.9) 4.4 (4.0–4.8) 6.4 (6.0–6.8) N.A. N.A. 5.8 (5.4–6.2) 8.9 (6.2–9.5)
OSRa = overall survival rate calculate by Kaplan-Meier method
RSRb = relative survival rate calculated using SEER*Stat 5.0
ASRc = absolute survival rate calculated by period analysis
RSRd = relative survival rate calculated by period analysis
N.A. = not available
Table 3: 10- and 15-year OSRa, RSRb, ASRc, RSRd for San Francisco-Oakland registry for 1981–1985 and 1991–1995 cohorts with 95% 
confidence intervals in brackets
San Francisco-Oakland
Year 1981–1985 1991–1995
OSRa RSRb ASRc RSRd OSRa RSRb ASRc RSRd
10 4.6 (2.8–6.4) 6.6 (4.2–9.0) 13.3 (12.3–14.3) 16.9 (15.7–18.1) 8.8 (5.7–11.9) 11.4 (7.9–14.9) 14.7 (13.7–15.7) 18.4 (17.2–19.6)
15 2.4 (1.2–3.6) 4.1 (1.9–6.3) 4.6 (4.2–5.0) 6.6 (6.0–7.2) N.A. N.A. 5.3 (4.9–5.7) 7.4 (6.8–8.0)
OSRa = overall survival rate calculate by Kaplan-Meier method
RSRb = relative survival rate calculated using SEER*Stat 5.0
ASRc = absolute survival rate calculated by period analysis
RSRd = relative survival rate calculated by period analysis
N.A. = not availableBMC Cancer 2004, 4:60 http://www.biomedcentral.com/1471-2407/4/60
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Requirements for using the lognormal model
The lognormal model can only predict cause-specific sur-
vival, because other coincidental causes of death are too
unpredictable (e.g., the rate of stroke). Therefore, overall
survival cannot be predicted. The maximum likelihood
method is the most accurate method for fitting the lognor-
mal model with the smallest mean squared error. How-
ever, there are some requirements for its use. The
maximum likelihood method fails to converge to a stable
solution using the initial estimates if there is extensive
censoring within the data. This occurs if patients are lost
to follow-up or die from coincidental non-cancerous
causes. The frequency of failure to yield a successful fit for
lognormality was greater when one-fourth of cases were
designated as lost to follow-up. Gamel et al. established a
stable linear algorithm for fitting the lognormal model to
survival data. To achieve convergence, some authors have
fixed one or two parameters of the lognormal model to
pre-selected values to simplify the iterative procedure
required for convergence [6].
Some prognostic factors follow lognormal distribution
Prognostic factors in patients with distant metastases at
the time of diagnosis were investigated by Rudan et al.
[16], and Chapman et al. [17], primary tumor size was a
significant prognostic factor. Engel et al. [18] found that
the number of metastatic cases and the time to metastasis
depended on the tumor diameter at diagnosis. Cell
growth is essential for the development of tumors. Tumor
size is therefore the most important factor in describing
tumor biology. As the tumor size increases, the probabil-
ity of node-positivity increases. Another study group also
found this correlation up to 5 cm [19]. Tubiana and
Koscielny [20] have found a highly significant correlation
between tumor size and the probability of distant metas-
tasis. The distribution of tumor sizes at metastatic spread
was lognormal with a median diameter equal to 3.5 cm.
The patients were subdivided into 3 groups according to
the histological grade. In each subgroup there was a signif-
icant correlation between tumor size and the probability
of distant spread. The distributions were lognormal and
the median size was markedly larger for grade 1 tumors.
A number of quantitative postmortem observations
regarding the size distribution of metastases have been
published [21-23]. These studies revealed a skewed distri-
bution with a high proportion of smaller metastases, and
a significant tail extending to the larger metastases, con-
sistent with a lognormal distribution. The more detailed
measurements from human liver metastases provided by
Yamanami et al. were found to approximate the lognor-
mal distribution reasonably well.
A hypothesis was proposed by Kendal [24] that the time
available for the growth of metastases is normally distrib-
uted, presumably as a consequence of the summation of
multiple independently distributed time intervals from
each of the steps and of the Central Limit Theorem. For
exponentially growing metastases, the corresponding size
distribution would be lognormal; Gompertzian growth
would imply a modified (Gompertz-normal) distribu-
tion, where larger metastases would occur less frequently
as a consequence of a decreased growth rate. These two
size distributions were evaluated against 18 human
autopsy cases where precise size measurements had been
collected from over 3900 macroscopic hematogenous
organ metastases. The lognormal distribution provided an
approximate agreement. Its main deficiency was a ten-
dency to over-represent metastases greater than 10 mm
diameter. These observations supported the hypothesis of
normally distributed growth times, and qualified the util-
ity of the lognormal and Gompertz-normal distributions
for the size distribution of metastases.
Why is the lognormal model applicable to so many organ
sites [3,6-10,12,25-36] (Table 4)? Boag's explanation for
the lognormal survival time distribution was that if the
patient was not cured by treatment, the length of the
remaining survival time would be dependent principally
on the growth rate of the tumor remnants. Pearlman [37]
estimated the growth rates of breast cancer that recurred in
the scar, assuming that the recurrence started from a single
cell. He found that the growth rates were approximately
lognormally distributed. Likewise, von Fournier et al. [38]
found that the growth rates of breast cancers followed by
serial mammography were lognormally distributed.
Variation of survival rates over time
In order to determine whether current programs for the
management of metastatic breast cancer have led to
improved patient survival, Debonis et al. [39] determined
the median survival times for five-year intervals of 849
patients admitted to the City of Hope National Medical
Center with metastatic breast cancer from 1955 to 1980.
Survival times in each of the clinical subsets remained
unchanged during the period of observation, regardless of
the therapeutic modalities included in the treatment regi-
mens. The study indicates that changes in palliative
therapy for metastatic breast cancer during the 25 years of
observation have not influenced overall survival. On the
contrary, Dickman et al. [40] studied the survival of cancer
patients in Finland during the years 1955–1994. The 5-
year RSR for distant metastases breast cancer had
increased from 10% for the period 1955–1964 to 22% for
1985–1994.
The tumor registry at Yale-New Haven Hospital, which
began recording data in 1920, was utilized by Todd et al.
[41] to examine the ultimate outcome of all breast cancer
patients who were initially diagnosed at Yale with meta-BMC Cancer 2004, 4:60 http://www.biomedcentral.com/1471-2407/4/60
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static breast cancer. The median survival of these patients
increased steadily from 21 months in 1920 to 41 months
in the decade from 1970 to 1980. The percentage of
women actually surviving 5 years increased from 5% in
the 1920s to approximately 25% in the 1960s. Despite the
use of combination drug programs in the 1970s, the per-
centage of these patients remaining alive at 5 years
remained near 25%. Firm conclusions cannot be made
from a retrospective study spanning 60 years, although
the trends depicted the lack of continued improvement
indicate that the current therapeutic approach to meta-
static breast cancer in that period may not result in dra-
matic improvement in overall survival.
Geographical variation of survival rates
Farrow et al. [42] documented substantial geographical
variation in patterns of treatment of cancer and other dis-
eases. Because cancer treatment is not uniform nation-
wide in the States, survival following the diagnosis of
cancer might also be expected to vary geographically. Sur-
vival data from the nine population-based registries in the
SEER Program were analyzed for cancers of the stomach,
colon, rectum, lung, breast, uterus, ovary, prostate, and
bladder. The patients included all non-Hispanic white
patients diagnosed with cancer of one of the selected sites
during 1983–1991. Regional variation in crude five-year
survival rates across the nine SEER areas was most marked
for cancers of the uterus and prostate. For uterine cancer,
for example, five-year survival ranged from 73.2% in Con-
necticut to 84.0% in Hawaii. Less marked variation was
observed for cancers of the colon, rectum, and breast. For
cancers of the bladder, ovary, stomach, and lung, survival
rates five years after diagnosis were relatively invariant
across the SEER areas.
Maggard et al. [43] also found that variations in the breast
cancer mortality rates exist between states. A nearly 50%
increase is observed between the states with the highest
and lowest mortality rates. Adjusted analyses demon-
strated that stage at presentation is a more important
predictor of mortality variation than treatment differ-
ences. Goodwin et al. [44] examined breast cancer inci-
dence, survival, and mortality in the 66 health service
areas covered by the SEER program for women aged 65
and older at diagnosis. They found that there was consid-
erable geographic variation in survival from breast cancer
among older women, and this contributed to variation in
breast cancer mortality. The elevated mortality in the
Northeast is apparent only in older women [45]. For
women aged 65 years and older, breast cancer mortality is
26% higher in New England than in the South, while inci-
dence is only 3% higher. Breast cancer mortality for older
women by state correlates poorly with incidence (r =
0.28).
Table 4: Cancer sites with survival times demonstrated to follow the lognormal distribution in the literature as at year 2004
Cancer sites Author
Head and neck cancer Berg [25], Mould[7]
Nasal sinus cancer Berg [25]
Mouth and throat cancer Boag [3]
Mouth Berg [25]
Thyroid Tai*[26]
Larynx, tongue Mould & Tai*[27]
Non small cell lung cancer Berg [25]
Small cell lung cancer Tai*[10]
Intraocular melanoma Gamel [8]
Cutaneous melanoma Gamel [9]
Breast cancer Boag [3], Berg [25], Rutqvist [5,15], Gamel [28,29], Haybittle [30], Royston [31], Tai*[12]
Bone sarcomas Berg [25]
Cancer of uterine cerivx Mould & Boag*[6], Berg [25]
Ovarian cancer Berg [25], Tai*[32], Royston [31]
Hypernephroma Berg [25]
Bladder cancer Berg [25]
Prostate Cancer Mould & Tai*[33]
Gastric cancer Berg [25], Maetani [34]
Lymphoma Berg [25]
Chronic leukemia Tivey [35]
Brain tumors Berg [25]
42 SEER cancer sites Tai [36]
SEER, Surveillance, Epidemiology, and End Results;
*, phase 2 validation also performed, i.e. concordance between Kaplan-Meier method and lognormal model.BMC Cancer 2004, 4:60 http://www.biomedcentral.com/1471-2407/4/60
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The above-mentioned results are consistent with that
from the present study: the Connecticut registry has lower
CSSR than the San Francisco-Oakland registry for the
period 1991–1995. The Connecticut cohort has median
age at diagnosis of 66 (range 25–103), while the San Fran-
cisco-Oakland cohort has lower median age of 63 (range
26–96). It could be argued that new treatments evolved in
the recent decade have improved the survival of the breast
cancer patients, and younger patients benefit more than
the older patients. Apart from treatment offered, changes
of survival rates over time or geographical areas can be
due to co-morbidities or other characteristics such as race,
age, and differences in staging procedures.
Conclusions
For the period 1981–1985, the 15-year cause-specific sur-
vival for the Connecticut and the San Francisco-Oakland
registries were comparable. For the period 1991–1995,
there was not much change in survival for the Connecticut
registry patients, but there was an improvement in sur-
vival for the San Francisco-Oakland registry patients.
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CSSR: Cause-specific survival. SEER: Surveillance, Epide-
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